Published December 2019 | Version v1
Journal article Metadata-only

Synchrotron Microbeam Radiation Therapy as a New Approach for the Treatment of Radioresistant Melanoma: Potential Underlying Mechanisms

Creators

  • 1. Institute of Anatomy, University of Bern, Bern (Switzerland)
  • 2. Synchrotron Radiation for Biomedicine, INSERM UA7, 71 rue des Martyrs, 38000 Grenoble (France)
  • 3. Joint Department of Physics, The Institute of Cancer Research and the Royal Marsden Hospital, London (United Kingdom)
  • 4. Biomedical Beamline ID17, European Synchrotron Radiation Facility, Grenoble (France)
  • 5. Department of Microbiology and Immunology, Center for Molecular Medicine and Stem Cell Research, Faculty of Medical Sciences, University of Kragujevac (Serbia)

Description

Synchrotron microbeam radiation therapy (MRT) is a method that spatially distributes the x-ray beam into several microbeams of very high dose (peak dose), regularly separated by low-dose intervals (valley dose). MRT selectively spares normal tissues, relative to conventional (uniform broad beam [BB]) radiation therapy.

Additional details

Identifiers

DOI
10.1016/j.ijrobp.2019.08.027;
PII
S0360301619336624;

Publishing Information

Journal Title
International Journal of Radiation Oncology, Biology and Physics
Journal Volume
105
Journal Issue
5
Journal Page Range
p. 1126-1136
ISSN
0360-3016
CODEN
IOBPD3

INIS

Country of Publication
United States
Country of Input or Organization
International Atomic Energy Agency (IAEA)
INIS RN
55057261
Subject category
S62: RADIOLOGY AND NUCLEAR MEDICINE;
Descriptors DEI
ANIMAL TISSUES; BEAMS; MELANOMAS; RADIATION DOSES; RADIOSENSITIVITY; RADIOTHERAPY; SYNCHROTRONS
Descriptors DEC
ACCELERATORS; BODY; CARCINOMAS; CYCLIC ACCELERATORS; DISEASES; DOSES; EPITHELIOMAS; MEDICINE; NEOPLASMS; NUCLEAR MEDICINE; RADIOLOGY; SENSITIVITY; THERAPY

Optional Information

Copyright
Copyright (c) 2019 The Authors. Published by Elsevier Inc.